Database Query Results : , , Src

Src, Src kinase: Click to Expand ⟱
Source:
Type: Oncogene
Src family of tyrosine kinases, which are a group of proteins involved in the regulation of various cellular processes, including cell growth, differentiation, and survival.
Src is overexpressed in several types of cancer, including breast, colon, lung, and prostate cancers.


Scientific Papers found: Click to Expand⟱
238- Api,    Apigenin inhibits TGF-β-induced VEGF expression in human prostate carcinoma cells via a Smad2/3- and Src-dependent mechanism
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vitro, Pca, C4-2B
VEGF↓, TGF-β↓, Src↓, FAK↓, Akt↓, SMAD2↓, SMAD3↓,
2016- CAP,    Capsaicin binds the N-terminus of Hsp90, induces lysosomal degradation of Hsp70, and enhances the anti-tumor effects of 17-AAG (Tanespimycin)
HSP90↓, ATPase↓, eff↑, HSP70/HSPA5↓, other↝, NF-kB↓, EGFR↓, CDK4↓, Src↓, VEGF↓, PI3K↓, Akt↓,
424- CUR,    Curcumin inhibits autocrine growth hormone-mediated invasion and metastasis by targeting NF-κB signaling and polyamine metabolism in breast cancer cells
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
Src↓, p‑STAT1↓, p‑Akt↓, p‑p44↓, p‑p42↓, RAS↓, Raf↓, Vim↓, β-catenin/ZEB1↓, P53↓, Bcl-2↓, Mcl-1↓, PIAS-3↑, SOCS-3↑, SOCS1↑, ROS↑, NF-kB↓, PAO↑, SSAT↑, P21↑, Bak↑,
4027- FulvicA,    Mummy Induces Apoptosis Through Inhibiting of Epithelial-Mesenchymal Transition (EMT) in Human Breast Cancer Cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7 - in-vitro, Nor, MCF10
tumCV↓, selectivity↑, TGF-β↓, Twist↓, NOTCH1↓, CTNNB1↓, Src↓, E-cadherin↑, EMT↓, TumMeta↓, BioAv↑,
830- GAR,    Garcinol modulates tyrosine phosphorylation of FAK and subsequently induces apoptosis through down-regulation of Src, ERK, and Akt survival signaling in human colon cancer cells
- in-vitro, CRC, HT-29
TumCI↓, TumCMig↓, Apoptosis↑, p‑FAK↓, Src↓, MAPK↓, ERK↓, PI3K/Akt↓, Bax:Bcl2↑, Cyt‑c↑, MMP7↓,
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,
4699- PTS,    Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, HS587T - in-vivo, BC, MDA-MB-231
TumCMig↓, TumCI↓, E-cadherin↑, Snail↓, Slug↓, Vim↓, Zeb1↑, miR-205↑, Src↓, TumCG↓, FAK↓, EMT↓,
3028- RosA,    Network pharmacology mechanism of Rosmarinus officinalis L.(Rosemary) to improve cell viability and reduces apoptosis in treating Alzheimer’s disease
- in-vitro, AD, HT22 - in-vivo, NA, NA
*Aβ↓, *Apoptosis↓, *antiOx↑, *neuroP↑, *eff↑, *IGF-1↑, *MMP9↑, *Src↓, *MAPK↓, *MMP↑,
2355- SK,    Pharmacological properties and derivatives of shikonin-A review in recent years
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, Apoptosis↑, TumAuto↑, Necroptosis↑, ROS↑, TrxR1↓, PKM2↓, RIP1↓, RIP3↓, Src↓, FAK↓, PI3K↓, Akt↓, mTOR↓, GRP58↓, MMPs↓, ATF2↓, cl‑PARP↑, Casp3↑, p‑p38↑, p‑JNK↑, p‑ERK↓,
3043- SK,    Shikonin Induces Apoptosis by Inhibiting Phosphorylation of IGF-1 Receptor in Myeloma Cells.
- in-vitro, Melanoma, RPMI-8226
IGF-1↓, Apoptosis↑, TumCCA↑, MMP↓, Casp3↑, P53↑, BAX↑, Mcl-1↓, EGFR↓, Src↑, KDR/FLK-1↓, p‑IGF-1↓, PI3K↓, Akt↓,
2197- SK,    Shikonin derivatives for cancer prevention and therapy
- Review, Var, NA
ROS↑, Ca+2↑, BAX↑, Bcl-2↓, MMP9↓, NF-kB↓, PKM2↓, Hif1a↓, NRF2↓, P53↑, DNMT1↓, MDR1↓, COX2↓, VEGF↓, EMT↓, MMP7↓, MMP13↓, uPA↓, RIP1↑, RIP3↑, Casp3↑, Casp7↑, Casp9↑, P21↓, DFF45↓, TRAIL↑, PTEN↑, mTOR↓, AR↓, FAK↓, Src↓, Myc↓, RadioS↑,
2083- TQ,    Thymoquinone inhibits proliferation in gastric cancer via the STAT3 pathway in vivo and in vitro
- in-vitro, GC, HGC27 - in-vitro, GC, BGC-823 - in-vitro, GC, SGC-7901 - in-vivo, NA, NA
p‑STAT3↓, JAK2↓, c-Src↓, Bcl-2↓, cycD1/CCND1↓, survivin↓, VEGF↓, Casp3?, Casp7?, Casp9?, *toxicity∅, TumVol↓,
119- UA,  CUR,  RES,    Combinatorial treatment with natural compounds in prostate cancer inhibits prostate tumor growth and leads to key modulations of cancer cell metabolism
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
ROS⇅, p‑STAT3↓, Src↓, AMPK↑,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 13

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Catalase↓, 1,   CYP1A1↓, 1,   GPx↓, 1,   GSH↓, 2,   GSR↓, 1,   GSTs↓, 1,   HO-1↓, 1,   NQO1↓, 1,   NRF2↓, 2,   PAO↑, 1,   ROS↑, 4,   ROS⇅, 1,   SOD↓, 1,   SOD2↓, 1,   TrxR1↓, 1,   VitC↓, 1,   VitE↓, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 1,   MMP↓, 1,   p‑p42↓, 1,   Raf↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   PI3K/Akt↓, 1,   PKM2↓, 2,   SIRT1↓, 1,   SSAT↑, 1,  

Cell Death ⓘ

Akt↓, 4,   p‑Akt↓, 2,   Apoptosis↑, 3,   ATF2↓, 1,   Bak↑, 1,   BAX↑, 2,   Bax:Bcl2↑, 1,   Bcl-2↓, 4,   Casp1↓, 1,   Casp3?, 1,   Casp3↑, 4,   Casp7?, 1,   Casp7↑, 1,   Casp8↑, 1,   Casp9?, 1,   Casp9↑, 1,   Cyt‑c↑, 2,   DR5↑, 1,   Fas↑, 1,   FasL↑, 1,   GRP58↓, 1,   HGF/c-Met↓, 1,   p‑JNK↑, 2,   MAPK↓, 2,   Mcl-1↓, 2,   p‑MDM2↓, 1,   Myc↓, 1,   Necroptosis↑, 1,   p‑p38↑, 2,   RIP1↓, 1,   RIP1↑, 1,   survivin↓, 1,   TRAIL↑, 1,  

Transcription & Epigenetics ⓘ

H3↓, 1,   H4↓, 1,   miR-205↑, 1,   other↝, 1,   tumCV↓, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   p‑eIF2α↑, 1,   HSP70/HSPA5↓, 1,   HSP90↓, 1,  

Autophagy & Lysosomes ⓘ

LC3II↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair ⓘ

DFF45↓, 1,   DNMT1↓, 1,   P53↓, 1,   P53↑, 2,   PARP↑, 1,   cl‑PARP↑, 1,   PCNA↓, 1,  

Cell Cycle & Senescence ⓘ

CDK4↓, 1,   cycD1/CCND1↓, 1,   P21↓, 1,   P21↑, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

CD34↓, 1,   cFos↑, 1,   CTNNB1↓, 1,   EMT↓, 4,   ERK↓, 1,   p‑ERK↓, 1,   HDAC↓, 1,   IGF-1↓, 1,   p‑IGF-1↓, 1,   mTOR↓, 3,   NOTCH1↓, 2,   PI3K↓, 3,   p‑PI3K↓, 1,   PIAS-3↑, 1,   PTEN↓, 1,   PTEN↑, 1,   RAS↓, 1,   Src↓, 9,   Src↑, 1,   p‑Src↓, 1,   c-Src↓, 1,   p‑STAT1↓, 1,   STAT3↓, 1,   p‑STAT3↓, 2,   p‑STAT6↓, 1,   TumCG↓, 1,  

Migration ⓘ

ATPase↓, 1,   AXL↓, 1,   Ca+2↑, 1,   Cdc42↓, 1,   CEA↓, 1,   CLDN1↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 2,   FAK↓, 5,   p‑FAK↓, 1,   ITGB1↓, 1,   MET↓, 1,   p‑MET↓, 1,   MMP13↓, 1,   MMP2↓, 1,   MMP7↓, 2,   MMP9↓, 1,   MMPs↓, 1,   N-cadherin↓, 1,   p‑p44↓, 1,   Rac1↓, 1,   Rho↓, 1,   RIP3↓, 1,   RIP3↑, 1,   Slug↓, 1,   SMAD2↓, 1,   SMAD3↓, 1,   Snail↓, 2,   TGF-β↓, 2,   TumCI↓, 2,   TumCMig↓, 3,   TumCP↓, 1,   TumMeta↓, 1,   Twist↓, 1,   Tyro3↓, 1,   uPA↓, 1,   Vim↓, 2,   Vim↑, 1,   Zeb1↑, 1,   ZO-1↑, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature ⓘ

EGFR↓, 2,   EGFR↑, 1,   Hif1a↓, 1,   KDR/FLK-1↓, 1,   VEGF↓, 5,  

Immune & Inflammatory Signaling ⓘ

ASC↓, 1,   COX2↓, 1,   ICAM-1↓, 1,   IKKα↓, 1,   IL2↑, 1,   IL6↓, 1,   JAK2↓, 1,   NF-kB↓, 4,   p‑p65↓, 1,   PD-1↓, 1,   SOCS-3↑, 1,   SOCS1↑, 1,  

Protein Aggregation ⓘ

NLRP3↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 2,   ChemoSen↑, 1,   eff↑, 1,   MDR1↓, 1,   RadioS↑, 2,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

AR↓, 2,   CEA↓, 1,   EGFR↓, 2,   EGFR↑, 1,   IL6↓, 1,   Myc↓, 1,   NSE↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   cachexia↓, 1,   chemoP↑, 1,   TumVol↓, 1,  
Total Targets: 186

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   Catalase↑, 1,   GPx↑, 1,   GSH↑, 1,   GSTs↑, 1,   lipid-P↓, 1,   SOD↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↑, 1,  

Cell Death ⓘ

Apoptosis↓, 1,   Casp3↓, 1,   MAPK↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

IGF-1↑, 1,   Src↓, 1,  

Migration ⓘ

MMP9↑, 1,  

Immune & Inflammatory Signaling ⓘ

IL10↑, 1,   IL1β↓, 1,   TNF-α↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 2,   Half-Life↝, 1,  

Functional Outcomes ⓘ

neuroP↑, 1,   toxicity∅, 1,  
Total Targets: 22

Scientific Paper Hit Count for: Src, Src kinase
3 Shikonin
2 Curcumin
1 Apigenin (mainly Parsley)
1 Capsaicin
1 Shilajit/Fulvic Acid
1 Garcinol
1 Luteolin
1 Pterostilbene
1 Rosmarinic acid
1 Thymoquinone
1 Ursolic acid
1 Resveratrol
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:291  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page